Please assess the completion status of the following clinical trial:

Trial Title: Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with resectable pancreatic cancer.~2. Histologically confirmed and/or based on radiological imaging and laboratory tests confirmed pancreatic cancer by multidisciplinary team for pancreatic tumors.~3. Age more than 18.~4. Life expectancy more than 3 months.~5. Performance status - Karnofsky ≥ 70 or WHO \< or 2.~6. Treatment free interval 2-5 weeks, depending on the drugs used.~7. Patient must be mentally capable of understanding the information given.~8. Patient must give informed consent.~9. Patient must be discussed at the multidisciplinary team for pancreatic tumors before entering the trial.~Exclusion Criteria:~1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or surgically or irradiated basal cell carcinoma.~2. Proven visceral, bone or diffuse metastases.~3. Life-threatening infection and/or heart failure and/or liver failure and/or renal failure (creatinine more than 150 µmol/L) other severe systemic pathologies.~4. Significant reduction in respiratory function.~5. Age less than 18 years.~6. Cumulative dose of 250 mg/m2 bleomycin received.~7. Allergic reaction to bleomycin.~8. Patients with epilepsy.~9. Patients with arrhythmias.~10. Patients with heart failure or pacemaker.~11. Pregnancy.~12. Patient incapable of understanding the aim of the study or disagree with the entering into the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP)

Based on this trial design, predict the completion outcome and termination type (if applicable).